Company intelligence / Profile preview

GIE Medical

Plymouth, Minnesota, United Statesgiemedical.com ↗

Ownership: Private
Development stage: Other

Overview

GIE Medical has developed a novel multi-stage drug-coated balloon technology called ProTractX3 TTS DCB for treating benign strictures of the gastrointestinal tract. The company has received FDA Breakthrough Device Designation for its esophageal indication and has launched multiple U.S. clinical trials in both esophageal and bowel strictures. Early results have led to continued enrollment in pivotal studies at major academic centers.

Therapeutic areas: Gastroenterology
Modalities: Device (Drug-coated balloon)Small molecule (Paclitaxel; as the drug coating)
Industry: Therapeutic Medical Devices

Partnerships

No major pharma partnerships disclosed; $5M strategic equity investment noted in late 2023

Beyond the preview

Go deeper on GIE Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GIE Medical.

Explore the full profile